Get Started

CRDL

NASD Cardiol Therapeutics Inc. Class A
Oct 26, 2026 · 8:42 AM ET LAST TRADE Market Closed

$1.11 ↓ -0.01 (-0.61%) Trading Down from the previous close of $1.12

YTD change
+16.71%
vs 20-day SMA
-14.20%
vs 200-day SMA
-14.32%

Price ranges

Previous day
$1.11 $1.16
open $1.15 close $1.12
-$0.03 (-2.61%)
Today
$0.00 $0.00
$1.11
Past week
$1.08 $1.19
from $1.10 now $1.11
+$0.01 (+1.20%)
Past month
$1.08 $1.71
from $1.71 now $1.11
-$0.60 (-34.90%)
This year
$0.90 $2.34
from $0.95 now $1.11
+$0.16 (+16.71%)

Price & Performance

-0.28 (-20.00%) / 6M

$0.8886$1.39$1.89$2.39Apr 27Jul 27Oct 23

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 77.6% away from all-time highs of $4.96
  • CRDL is up 17% since the beginning of the year
  • CRDL is down 6% over the past 12 months
  • CRDL is down 35% over the past 1 month
  • 4% of all CRDL investors are betting against CRDL

CRDL reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -8.2%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.0358603
Earnings momentum +42.3% Quarterly EPS growth
Quarterly change +42.3%

Valuation

P/E ratio N/A
Enterprise value $112.4M
Beta 1.00

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$18.4M
Debt$75.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $129.0M

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the "ARCHER" trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Competitor comparison

TickerCompany PriceChange
DD DuPont de Nemours, Inc. $136.55 +1.07%
JDHIY JD Health International, Inc. Unsponsored ADR $5.09 +8.76%
COIHY Croda International Plc Unsponsored ADR $24.08 -0.37%
JWEL.CAT JAMIESON WELLNESS INC $45.49 -0.09%
TRLV Trulieve Cannabis Corp. $10.42 -4.58%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.